News

Keep up to date. Have a look at what Volv has been working on, what we have been publishing or which events we have been attending. Some of the events include videos you might want to review.

20220627 Volv Logo at WODC 2022
World Orphan Drug Congress (WODC) USA 2022Held in Boston July 11th - 13th 2022Volv are Platinum Sponsors

To help rare disease innovators establish a better clinical development strategy, Volv is conducting an in-depth Workshop at the WODC USA, and will announce a new offering called inClude. We help customers create new ways to reach more patients at lower cost than has been achieved before.

RWE
World Rare Disease Day 2021 - Real World Evidence PanelVideo of panel discussion on RWE

Christopher Rudolf, Founder and CEO of Volv Global SA, took part in the panel with Martine Zimmermann, Global Head of Regulatory Affairs, Alexion Pharmaceuticals, Inc, Javier Jimenez, EVP RWE & Late Phase, Syneos Health and Matt Eagles, Head of Patient Engagement, Havas Lynx Group to discuss RWE and patient-centricity for World Rare Disease Day.

Volv PR graphic Linked In
Scailyte and Volv announce strategic partnership to accelerate rare disease patient diagnosisScailyte and Volv announce strategic partnership to accelerate rare disease patient diagnosisRare oncologic & immune disease diagnostics

Artificial Intelligence (AI)-driven biomarker discovery innovators Scailyte and Volv, today announced a strategic partnership to develop a patient identification and diagnostic platform for rare diseases.

4384 Gene Therapy 2020 Logo
4th Annual Gene Therapy for Rare Disorders USA - VirtualBuilding Your Gene Therapy Value Story From Day OneVolv Global - Partner sponsor

Determining patient prevalence with rare and ultra-rare diseases has long been a challenge for industry, investors and payers. Accurate prevalence data, along with the ability to locate patients that could benefit from a breakthrough ATMP, will enable companies to present their value story from the start of the R&D journey. Come and see us talk about this and more at the event.

WODC USA Video1
World Orphan Drug Congress (WODC) 2020 USA - Virtual EventAt the WODC virtual event we talked about what we do in AI for rare diseases and personalised medicines

Volv were excited to be at the World Orphan Drug Congress virtual event as Platinum sponsor. People have requested that the video of our Presentation be reposted online, as they missed it at the event, so here it is.

Haybale
Article: Finding and treating rare disease patients in the digital haybaleArticle in Journal for Clinical StudiesEnabling better identification and diagnosis by combining EMR data analysis and AI

Healthcare: The Big Shark Tank Our healthcare ecosystem has also gone the same way. Today, healthcare is no longer a house call by a local doctor who knows our history by simple familiarity and through their own paper records. . .

Clinerion Article
Article: Rare Diseases and the way forwardArticle by Douglas Drake from ClinerionEnabling better identification and diagnosis by combining EMR data analysis and AI

February 29th, 2020, is not only a rare leap year day, but also Rare Disease Day, an observance organized by the European Organization of Rare Diseases (EURORDIS) and supported by the National Organization of Rare Diseases (NORD) to raise awareness for unknown or overlooked illnesses.[...]

WODC in Trigue
World Orphan Drug Congress (WODC) EU 2019World Orphan Drug CongressHeld in Barcelona

Volv is Gold Sponsor at the World Orphan Drug Congress 2019 in Barcelona.

IH 2019 Sponsor 1500x500
Intelligent Health 2019Basel 19 Sept 2019Volv Global Sponsors

Launch of Volv's new product and focus: inCognita for Neurodegenerative Diseases.

Video Onco
Volv Video COSVideo of Christopher Rudolf Interviewedat the Convergence in Oncology summit

Christopher Rudolf, Founder and CEO of Volv, took part in the panel "Digitalisation at the Service of Oncology, from Prevention to Monitoring".

Innovation Leaders2019 Social Media Horizontal 1024x535
Volv @ EPFLInnovation Leaders Event2 May 2019 EPFL Rolex Center

https://emba.epfl.ch/event/innovationleaders19/

Vg Data Science Net
AI in PharmaBerlin 2019Volv Chairing the Event

Discover latest AI trends and developments within Pharma and network with professionals across both industry and academia.

AMIA2018
Paper Published at AMIAAnnual SymposiumAMIA 2018 Annual Symposium in San Francisco

Rich Colbaugh, Head of Data Science at Volv will be presenting some of our most recent publications at AMIA

Vg Data Science Net
Paper Published at IEEEIEEE International Conference on Systems, Man, and Cybernetics MiyazakiVolv Publishes a paper on patient finding in EHRs

Kristin Glass, Computational Science Lead at Volv will be presenting some of our most recent publications at IEEE

Emp Found
Empowerment Summit - AIVolv will be participating in a workshop

To take stock of the integration of AI in medicine and, if possible, to agree on action points to stimulate projects integrating IA and medicine

Conv Oncol
Convergence In OncologyConferenceConvergence In Oncology

Real Results R&D Progress Transfer of Techniques Relevant Oncology Solutions

IEEE Honolulu
Paper Published at IEEEIEEE Engineering in Medicine and Biology Society HonoluluVolv Publishes a paper on patient finding in EHRs

Kristin Glass, Head of Computational Science at Volv will be presenting some of our most recent publications at IEEE

Vg corvus gtc event
Global Clinical Trials Connect2018 Conference in LondonVolv presenting on how new approaches in Data Science can help with rare diseases

The Global Clinical Trials Connect 2018 Conference focuses on introducing pioneer technology, developing better patient engagement, and collaborating strategically in clinical trials.

Pexels photo 640
AI SummitArtificial Intelligence in Pharma Industry SummitBerlin February 19/20

Volv will be speaking at the Artificial Intelligence in Pharma Industry Summit Berlin February 19/20

Vg Gold AI Congress Square
World AI CongressLondon O2 January 30/31 2018Volv Global - Gold sponsor

We help customers create new ways to provide treatments that reach more patients and at lower cost than has been achieved before.